Data Editor, Pharma
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From John Hodgson
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.
What does a good drug launch look like? Is pharma getting better at them? Which drugs are likely still to be in the top 20 in five years' time? Get the picture with Scrip's interactive infographic.
Investments of over $100 million are now close to becoming the predominant class of venture capital deployed in the life sciences. What is behind this shift in venture investing and how might it impact companies' strategy to attract the big bucks.
The story of the first quarter of 2018 is the impact of the general stock downturn at the end of January and the selective recovery that followed. But even though AbbVie and others had their own private yo-yos, the real correction took a while.
Keith Blundy, CEO of STORM Therapeutics, discusses the company’s founding and upcoming milestones.
Stephan Christgau, a senior partner at Novo Holdings, talks about the firm’s approach to early-stage funding in biotech and how this financing arm aligns with Novo’s broader strategy.